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1. Introduction   
Pancreatic ductal adenocarcinoma (PDAC) devours two American lives every 30 minutes 
(annual death rate >37,000) and is the fourth leading cause of cancer-related deaths in the US 
(Jemal et al. 2010). Median survival is 4 to 6 months and the 5-year survival is less than 5% 
(Baxter et al. 2007). The standard chemotherapeutic agent gemcitabine shows dismal response 
rate and has little impact. Recently, clinicians have incorporated platinum-based genotoxic 
regimens such as oxaliplatin nevertheless such combinations have little impact on improving 
the overall survival of PDAC patients (Wang et al. 2011). There are critical unanswered 
questions regarding the mechanism of drug failure in PDAC and investigations are still a long 
way from identifying novel drug combination regimens to achieve cure. Therefore, 
management of PDAC is an ongoing challenge and novel clinically-translatable therapeutic 
agents that can improve on the dismal survival statistics of PDAC are urgently needed.  
To date, PDAC carcinogenesis and drug resistance are only partly understood, due to the 
heterogeneity of this disease at the cell/tissue level. In general carcinogenesis progresses 
through the accumulation of genetic alterations resulting in a gain of cell growth and 
proliferation, and subsequently, in increased dissemination and metastatic potential and 
PDAC is not an exception (Whitcomb and Greer 2009). Loss or gain of gene function may 
appear in the form of up-regulation of oncogenes, down-regulation of tumor suppressor 
genes, and deregulation of genomic maintenance/DNA repair genes, house-keeping genes, 
and genes that control the apoptosis/cell death/immortalization cascade (Sohn 2002; 
Hruban et al. 2007; Hruban et al. 1999). PDAC arises from precursor lesions called pancreatic 
intraepithelial neoplasms (PanINs), which are characterized by the sequential accumulation of 
alterations in the K-ras oncogene and loss of the CDKN2A, TP53 (p53), and/or SMAD4 tumor 
suppressors (Hruban et al. 2000). Although we know the frequencies of such mutations in 
PDAC, their specific functions during the development of PDAC remain unclear. K-ras and 
p53 are considered to be among the most critically deregulated genes that participate in cross 
talk to render PDAC therapy resistance (Hollstein et al. 1998; Hollstein et al. 1994). In the 
forthcoming passages we will first describe the impact of de-regulated p53 signaling on 
therapy resistance and then update on the pharmaceutical progress of small molecule 
inhibitors against p53 and related targets for the treatment of PDAC.   
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2. Impact of dysfunctional p53 signaling on PDAC therapy resistance  
p53 tumor suppressor gene is mutationally inactivated in >50% of PDAC (Hohne et al. 1992; 
Kalthoff et al. 1993), predominantly through missense mutations (Pellegata et al. 1994). 
These often result in accumulation of mutant p53 protein, with potentially gain-of-function 
or dominant-negative properties. The fact that p53 is mutated, rather than deleted, in the 
majority of PDAC suggests that mutant p53 provides some tumor cell growth advantage. 
Murine models support this as mice expressing the accumulating p53 mutants p53R172H or 
p53R270H have increased incidence of osteosarcoma and epithelial carcinomas, some of which 
spread to distant organs (Lang et al. 2004; Olive et al. 2004). In contrast, mice that harbor a 
p53 null allele rarely develop metastases. It has also been recognized that mut-p53 and 
family member p63 protein can inhibit wt-p53 function, indicating that bi-allelic inactivation 
may not be necessary for loss of function. The third family member, p73, is rarely mutated 
and has been shown to possess apoptotic function in response to small molecule inhibitors 
and platinum drugs-induce apoptosis. Furthermore, in the other 50% of PDAC, the p53 gene 
is normal (wild type wt-) but its function is inhibited by MDM2 (human double minute 2); a 
protein that is over expressed in PDAC and is the primary focus of this chapter.  
The activity of wt-p53 is mainly regulated at the post-translational level through its 
proteolytic turn over (Brooks and Gu 2006). This is achieved through the interaction with 
MDM2, which induces wt-p53 degradation by ubiquitin-mediated proteolysis (Bottger et al. 
1997). In normal, non-stressed cells, MDM2 induces p53 degradation constantly, making it a 
short-lived protein. However, in response to DNA damage, MDM2 is auto-poly-
ubiquitinated, resulting in its degradation and an associated increase in p53 levels and 
activity. This regulatory mechanism is subject to a feedback loop since p53 in turn, regulates 
the level of MDM2 transcription, giving rise to subtle balances between the amounts of p53 
and MDM2 (Fig1) (Lahav 2008; Bose and Ghosh 2007). Although other isoforms of MDM2 
are also present, i.e. HDM4 (Mancini et al. 2009a; Okamoto et al. 2009; Mancini et al. 2009b), 
but carry have lesser impact on p53. Despite being an energy consuming process, the 
MDM2-post-translational regulation of the amount of p53 is advantageous for cells because 
it is rapid and it increases the odds of having functional p53 following genotoxic stress and 
is in contrast to transcriptional regulation which is slower and sensitive to DNA damage 
(Millau et al. 2009). A common Mdm2 promoter polymorphism is the T→G transformation 
at nucleotide 309. This Mdm2 309T/G promoter polymorphism has been associated with the 
development of a variety of tumors including PDAC (Grochola et al. 2010b; Bond et al. 2004; 
Ohmiya et al. 2006b; Galic et al. 2007; Lind et al. 2006). Its significance in clinical outcome is 
not well outlined, but recent associations with prognosis have been found in lung and 
gastric cancer (Ohmiya et al. 2006a). The G allele is associated with increased affinity for Sp1 
binding and higher MDM2 mRNA and protein levels, leading to diminished tumor 
suppressor activity of the p53 pathway (Iwakuma and Lozano 2003). Over-expression of 
MDM2 in cancers prevents this normal balance and thus inhibits p53 even though it may 
not be mutated (bdel-Fattah et al. 2000; Watanabe et al. 1994; Watanabe et al. 1996). Based on 
functional significance of MDM2 in the biology of p53, one attractive pharmacological 
approach to wt-p53 activation is to use a small molecule weight inhibitor (SMI) to block the 
MDM2–p53 interaction (Klein and Vassilev 2004; Secchiero et al. 2008; Vassilev 2004b). 
Further, it is well recognized that genotoxic drugs such as oxaliplatin work through 
activation of p53 signaling, however, mutations in the gene or over-expression of MDM2 is 
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logical to thwart proper p53 response and therefore diminish the therapeutic potential of 
these drugs. Thus, re-activation of p53 by blocking MDM2 is an attractive pharmacological 
approach for treatment MDM2 over expressing subtype of PDAC (Azmi 2011; Azmi et al. 
2010c). Nevertheless, there are additional de-regulated signaling molecules and p53 
masking mechanisms that come into play. It is the lack of understanding of these regulatory 
control mechanisms that had led to failure in the effective design of drugs. As discussed 
below, the success of novel drugs is possible if the proper combination is identified that hits 
each component of the PDAC resistant network to achieve clinically beneficial outcome.   
 
Fig. 1. MDM2 is a Master Regulator of p53: MDM2 blocks p53 activity at multiple levels. (1) 
MDM2 can bind directly to p53 activation domain and suppress its transcription. (2) MDM2 
acts as E3 ligase and promotes p53 proteasomal degradation. (3) MDM2 has a nuclear export 
signal sequence in its domain structure that is responsible for p53 nuclear export. 
Cytoplasmic retention of p53 suppresses its nuclear transactivation activity. (4) MDM2 can 
block post-translational modifications of p53 (acetylation, phosphorylation etc necessary for 
p53 activity). (5) In turn, the transcription of MDM2 is regulated by p53. (Adopted from 
Azmi et al. 2011)  
2.1 Regulation of p53 by hedgehog driven K-ras-snail axis  
PDAC is an oncogenic K-ras driven disease and it is well established that majority of PDAC 
tumors show alteration in this pathway (Laghi et al. 2002). Although 3 kinds of oncogenic 
Ras have similar roles in induction of cell proliferation, survival, and invasion through the 
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stimulation of several pathways (Downward 2003), the mutation rate of K-ras is relatively 
higher than others, which indicates that the genetic alteration of K-ras is a major driving 
force for PDAC. Recently, the regulatory network of mutant K-ras signaling on p53 pathway 
has been established. Studies indicate that in cancer, p53 activity is suppressed via a novel 
mechanism of K-ras activation and consequent stabilization of snail (Fig2).   
 
Fig. 2. Schematic diagram showing snail-p53 interaction that suppresses therapeutic 
response of genotoxic p53 re-activating regimens. Snail is activated through oncogenic K-ras 
driven ATR pathway while genotoxic regimens additionally induce snail. Novel agents 
targeting snail can have therapeutic implications against K-ras driven PDAC. 
Snail stabilization occurs through activated ATR in K-ras mutated cells that demonstrates a 
strong direct interaction between snail and DNA-binding domain of p53, resulting in 
elimination of both protein from the cells (Horiguchi et al. 2009). This novel regulatory 
network has been shown to be independent of MDM2 or ARF-mediated p53 regulation. In 
normal cells, activation of oncogenic K-ras has been shown to provoke apoptosis or 
senescence through p53 activity, indicating that the loss of functions through p53 mutation 
is inevitable for the tumor progression by oncogenic K-ras (Gorgoulis and Halazonetis 
2010). In mouse models, the adenoma is evoked by oncogenic K-ras despite the intact p53 
system, which highlights that the additional and unique function of K-ras may enable cancer 
cells to avoid the tumor suppressive function of p53. Recent studies have also demonstrated 
the apparent tumorigenic function of oncogenic K-ras in mouse cell transformation (White 
et al. 2011). While normal mouse fibroblast transfected with N- or H-ras induce apoptosis or 
senescence, K-ras12V transfected cells become resistant and this is consistent with the 
multistep carcinogenesis model of colon or PDAC. In fact, genetic mutations of K-ras occur 
in the early adenoma stage without p53 mutation. However, large portion of adenoma can 
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be progressed into carcinoma without impaired p53 system or consequent apoptosis or 
senescence. These observations strongly indicate that oncogenic K-ras-snail axis possesses 
strong p53 suppressive effects downstream of MDM2 that cannot be ignored. Additionally, 
hedgehog signaling that is considered driver for PDAC induces Gli that in-turn induces 
snail adds to the existing ATR-driven suppressive mechanisms (Marigo et al. 1996). Thus, 
strategies that overcome these inhibitory pathways need to be incorporated in any genotoxic 
regimen that targets activation of p53 system. In sum, these findings demonstrate that in 
addition to MDM2 suppression targeting p53-snail binding can bring additional benefit to 
genotoxic therapy to achieve clinically superior therapeutic effects in PDAC.  
Because the interaction between MDM2 and p53 is a primary mechanism for inhibition of 
the p53 function in cancers retaining wild-type p53, targeting the MDM2-p53 interaction by 
small molecules to reactivate p53 has emerged as a promising new cancer therapeutic 
strategy. In this chapter, the emerging SMIs of MDM2-p53 interaction are evaluated with 
additional discussions on new snail-p53 interaction inhibitors for the treatment of pancreatic 
cancer.  
3. Reactivating the wild-type p53 
Inhibition of p53 activity in tumors by the increased expression of MDM2 has been the 
target of development for many small-molecule-, peptide- and aptamer-based therapies 
(Lehman et al. 2008). MDM2 is over expressed in many human tumors including PDAC, 
often owing to an amplification of a chromosome segment that includes Mdm2, although 
over expression of the protein is possible without gene amplification (Do et al. 2009; 
Assmann et al. 2009; Shinohara et al. 2009; Grochola et al. 2010a; Lang et al. 2009; 
Economopoulos and Sergentanis 2009; Perfumo et al. 2009). There has been extensive 
validation of MDM2 as a target, ranging from studies with aptamers and peptides through 
to antisense approaches and, perhaps most significantly, was described in a path breaking 
study using a hypomorphic allele of Mdm2 in the mouse (Mendrysa et al. 2003). In this 
study, nominal reductions in MDM2 levels were found to be sufficient to trigger a mild p53 
response (as shown by increased levels of lymphopenia and apoptosis in intestinal crypts) in 
response to increased p53 activity. The volume of the thymus is also reduced and there is a 
small effect on weight gain during development. Gene dosage studies have found levels of 
MDM2 that selectively inhibit the development of colon carcinoma induced by the absence of 
adenomatous polyposis coli (APDAC) without adverse affects on normal tissues. These 
powerful studies provided proof of a therapeutic index for MDM2 inhibition that has now 
been confirmed by the first small molecule candidates, including Nutlin (Vassilev et al. 2004), 
MI-219 (Shangary and Wang 2009) and reactivation of p53 and induction of tumor cell 
apoptosis (RITA) also known as NSC 652287 (Hedstrom et al. 2009), which produce tumor 
regression in vivo in human tumor xenografts in nude mice. These initial studies paved way 
for large scale investigations on different types of MDM2 inhibitors and are discussed below. 
3.1 Non-peptidic small-molecule inhibitors of MDM2-p53 interaction 
The progress in the design of nonpeptidic, small-molecule inhibitors of the MDM2-p53 
interaction (mentioned herein as MDM2 inhibitors; sometimes also called as MDM2i 
inhibitors) proceeded very slowly for almost a decade after the publication of the crystal 
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structures. The very first class of bona fide, potent, nonpeptidic, small-molecule MDM2 
inhibitors, known as Nutlins, was reported in 2004 (Vassilev 2007; Vassilev 2005; Vassilev 
2004a). The Nutlins contain a cis-amidazole core structure and one analogue, Nutlin-3, has 
potent in vivo antitumor activity in xenograft models of human cancer-retaining wild-type 
p53. The discovery of the Nutlins provided the important proof-of-concept and fueled 
enthusiasm for the design and development of small-molecule MDM2 inhibitors. In the last 
4 years, several new classes of small-molecule MDM2 inhibitors have been discovered using 
different approaches (Canner et al. 2009; Shangary et al. 2008a; Fotouhi and Graves 2005). 
Using a computational structure-based de novo design strategy, a new class of spiro-
oxindoles that are potent inhibitors of MDM2 (Ding et al. 2006), as exemplified by MI-63 and 
MI-219 were designed. In this regard Nutlin-3 a cis-imidazole has been well studied in 
different cancers. Our MI series of MDM2 inhibitors belong to different class (spiro-
oxindole) and have a slightly higher affinity towards MDM2 when compared to Nutlins. 
Using a structure-based de novo design strategy it was shown that the interaction between 
p53 and MDM2 is primarily mediated by four key hydrophobic residues (Phe 19, Leu 22, 
Trp 23 and Leu 26) of p53 and a small but deep hydrophobic cleft in MDM2. Nutlin-3 
mimics the interactions of the p53 peptide to a high degree, with one bromophenyl moiety 
sitting deeply in the Trp pocket, the other bromophenyl group occupying the Leu pocket, 
and the ethyl ether side chain directed toward the Phe pocket. In essence, the imidazoline 
scaffold replaces the helical backbone of the peptide and is able to direct, in a fairly rigid 
fashion, the projection of three groups into the pockets normally occupied by Phe19, Trp23, 
and Leu26 of p53. However, unlike Nutlin-3 in case of our inhibitors (MI series), 
computational modeling predicted that MI-219 mimics the four (instead of three in case of 
Nutlin-3) key binding residues in p53 (Phe-19, Leu-22, Trp-23 and Leu-26) resulting in 
optimal hydrogen bonding and hydrophobic interactions with MDM2. Both Nutlins and 
MI-219 enter many types of cultured cells and inhibit the p53–MDM2 interaction with a high 
degree of specificity, leading to the stabilization of p53 and the activation of the p53 
pathway. Proliferating cancer cells that express wild-type p53 are effectively arrested in the 
G1 and G2 phases of the cell cycle or can undergo apoptosis when treated with micro molar 
concentrations of Nutlins (Shangary et al. 2008b). This indicates that some cells are more 
susceptible to Nutlin-induced apoptosis than other cells in which a reversible cell cycle 
arrest is observed. The key cellular characteristics that underlie this difference in response 
are the subject of intense investigation. This differential response may occur owing to 
abnormalities further downstream in the p53 pathway. Other small molecules that have 
been developed to target the p53–MDM2 interaction include benzodiazepenes (Patel and 
Player 2008). The benzodiazepene-based derivatives disrupt the MDM2–p53 interaction in 
vitro with IC50 values of 0.5–2 µM and have also been shown to suppress the growth of cell 
lines containing wild-type p53. Administration of the benzodiazepene derivative 
TDP665759 to normal mice led to an increase in p21 (also known as WAF1 and CIP1) levels 
in liver samples (Koblish et al. 2006). Finally, TDP665759 synergizes with doxorubicin both 
in culture and in xenografts of A375 melanoma cells to decrease tumor growth.  
With so many targets identified against the MDM2-p53 interaction and supporting 
preclinical laboratory evidence it is imperative that effective MDM2 inhibitors will become a 
major form of therapy in the coming years. However, several potential drawbacks to 
targeting the MDM2–P53 interaction can be envisioned. First, MDM2 is induced by p53 
activation as part of an inducible feedback loop that negatively regulates the p53 response. 
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Therefore, the drugs would induce their target, limiting their potential efficacy. Second, the 
current molecules fail to effectively target MDM4. The binding pocket of the N terminus of 
MDM2 has shown itself to be eminently druggable, and a future challenge is whether or not 
these drugs can proceed to the clinic and whether they can also be refined to target other 
MDM2 family members such as MDM4. Apart from this avenue of research, other target 
sites have been identified in this p53 regulatory pathway that show the potential for drug 
development, and it remains to be seen if they generate therapeutic leads that have low 
toxicity in normal tissues. 
3.2 Compounds that target p53 regulators 
Activated p53 is under multiple post-translational control that includes acetylation, 
methylation, phosphorylation, neddylation and sumoylation (Lee and Gu 2010; Kruse and 
Gu 2009; Halaby and Yang 2007; Schumacher and Gartner 2006; Chuikov et al. 2004; Haupt 
2004; Brooks and Gu 2003; Wiederschain et al. 2001; Somasundaram 2000; Craig et al. 1999). 
Activating p53 using small may not be sufficient for proper p53 function and combinations 
with agents that suppress post-translational p53 blockers such as acetylation would benefit 
the overall outcome of such therapy. An example of this type of agent which was identified 
through a p53-based phenotypic screen are tenovin-1 and its more water-soluble derivative 
tenovin-6 (Lain et al. 2008; Brooks and Gu 2008). Tenovins rapidly increase p53 levels in cells 
treated with low micro molar concentrations, and daily intraperitoneal injection of tenovin-6 
at 50 mg per kg delays xenograft tumor growth in mouse models. Through a yeast genetic 
screen and subsequent enzymatic assays tenovins were shown to inhibit the NAD+-
dependent deacetylase activity of SIRT1 and SIRT2 (Canto and Auwerx 2009; Campisi and 
Yaswen 2009), two members of the sirtuin family of class III histone deacetylases. p53 
deacetylation by SIRT1 impairs p53 stability and transcriptional activity. Therefore, 
inhibiting the sirtuins should lead to increased p53 stability. Indeed, treatment of MCF-7 
cells with tenovins led to the accumulation of acetylated p53 and acetylated tubulin, which 
are established substrates of SIRT1 and SIRT2, respectively. Further chemical optimization 
of the potency of the tenovins is now possible owing to the elucidation of SIRT1 and SIRT2 
as the cellular targets. The discovery and characterization of the tenovins is an example of 
how current technological advances in target identification and p53 basic research 
contribute to the understanding of the mechanism of action of bioactive small molecules. 
3.3 Snail-p53 interaction inhibitors 
Rapid progress has been made in the development of novel chemicals which can block the 
K-Ras-mediated p53 suppression through the screening of the chemical library. Using 
ELISA-based chemical screening for discovering potent chemical inhibitors that are effective 
to prevent the binding were discovered. Interestingly, one group of the chemical library 
particularly showed high effects in blocking the interaction of Snail and p53 (Lee et al. 
2010b). Since this chemical library was arranged in accordance with its chemical structural 
similarity, it strongly implies that the similar structural motif of chemicals can impact p53-
snail interaction. Among the compounds of this group, B3 and C2 were selected as 
candidates that could effectively provoke p53 and its target genes, such as p21 and PUMA, 
in K-Ras mutated cancer cell lines (Lee et al. 2009a). GN25 and GN29 has been revealed to 
show substantial results that induce p53 and p21 expression, as much as Nutlin-3 (small 
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molecule inhibitor that specifically blocks p53-MDM2 binding). Strong candidates (GN25 
and GN29) can activate the p53 in K-Ras mutation dependent manner (Lee et al. 2010a) (Fig 
2). GN chemicals show similar activity on p53 activation only in K-Ras mutated cell. 
Moreover, GN25 shows no cytotoxic effect in normal or K-Ras wild type cancer cells.  
Of importance is the observation that GN chemicals can induce p53 and p21 occurred as 
strong as in the treatment of DNA damaging agents such as adriamycin or etoposide, and 
the anti-proliferating effect of GN chemicals was even stronger than Nutlin-3. In addition, in 
normal fibroblast, any significant differences not only on the p53 expression level, but also 
on its proliferation and viability was not detectable by GN chemicals, but by Nutlin-3, which 
reveals that GN chemicals possess the powerful and specific property unique to other 
chemicals. The extensive duration of the p53 activity response to low concentration of GN25 
and GN29 was shown for over 24 hours, which indicate that these chemicals successfully 
remedy problem of very short re-activation of p53. One crucial fact is that another additional 
derivative, GN25-1 containing the same side chain but a modified nuclear structure of 
GN25, has no effect on the induction of p53, which suggest that the conserved nuclear 
structure of the GN chemical is critical in increasing p53 activity.  
In the condition of disrupted Snail, p53 induction could be shown in K-Ras mutated cancer 
cells, but there is no synergic and additional effect by GN25 and 29, which clearly indicate 
that p53 induction by GN25 and 29 can occur through interfering Snail-p53 binding. To 
identify the specificity of these chemicals on Snail-p53 binding, several surrounding factors 
involved in the p53 function should be checked. Since the middle region of Snail is normally 
targeted for CK1/GSK3β-dependent phosphorylation (Cano et al. 2000). In addition, 
although p53 has no influence on β-Catenin phosphorylation by CK1/GSK3β, recombinant 
p53 sufficiently interferes with CK1/GSK3β-mediated Snail phosphorylation (Yook et al. 
2006). Indeed, quercetin (inhibitor of Snail-p53 binding) and GN25 could recover CK1/GSK-
3β-mediated Snail phosphorylation even in the presence of p53 (Lee et al. 2009b). In 
contrast, GN25 did not affect the physical interaction of p53 with other proteins such as 
WRN making it a p53 specific targeted SMI (Blander et al. 1999).  
One of very exciting feature is that GN25 and GN29 block the interaction between Snail with 
wild type p53 but not with mutant type p53. This is resulted from the property of chemicals, 
which can bind to wild type p53. Indeed, GN chemical can rescue the only wild type p53 in 
wild and mutant p53 expressed cells from K-Ras or Snail-mediated p53 suppression. Thus, 
GN chemical can work in p53 mutated cancer cells, if it possesses single copy of p53. In fact, 
although GN25 and 29 decrease total p53 expression level in p53 WT/MT cells (no effect on 
the transcriptional level), it can induce p21 and PUMA and reduce the proliferation and 
viability of cells. This result was not accomplished by other DNA-damaging agents 
including Adriamycin or Nutlin-3. By the use of GN chemicals, all of the p53 proteins might 
be protected from Snail-mediated elimination in p53 WT/WT status. These features of GN 
chemical can extend the application range from p53 wild type cancer to p53 mutated cancer 
and from early cancer to late stage cancers.   
4. MDM2 inhibitor investigations in PDAC  
Testing of MDM2 inhibitors have been restricted in PDAC and this may be due to lack of 
suitable cell lines (Capan-2 is the only wt-p53 PDAC cell line). To this end our laboratory is 
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the first to show the growth inhibitory and apoptotic potential of MDM2 inhibitors MI-319, 
MI-219 and Nutlin-3 in PDAC (Azmi et al. 2010b). These inhibitors specifically induced cell 
growth inhibition and apoptosis in wt-p53 PDAC cells. Growth inhibition and apoptosis by 
MDM2 inhibitors was accompanied by increase in levels of p53 along with p21WAF1 and the 
proapoptotic Puma. In these studies immunoprecipitation-western blot analysis revealed 
reduced association of MDM2-p53 interaction in drug exposed PDAC cells. Further, using 
wt-p53 xenograft of Capan-2, we found that oral administration of MI-319 at 300 mg/kg for 
14 days resulted in significant tumor growth inhibition without any observed toxicity to the 
animals. No tumor inhibition was found in mut-p53 BxPC-3 xenografts. We also explored 
combination treatments of these inhibitors with chemotherapeutics such as gemcitabine and 
cisplatin. Interestingly MI-319, MI-219 combination specifically enhanced cell growth 
inhibition and apoptosis in PDAC cells with wt-p53 suggesting that this potent combination 
can be used in the clinic for wt-p53 population in this dreadful disease. We also tested the 
combination of MI-319 with cisplatin which although less popular for PDAC yet is a potent 
p53 inducer. Apart from being a potent combination in wt-p53 PDAC tumors most 
interestingly MDM2 inhibitor-cisplatin combination drastically induced growth inhibition 
apoptosis and tumor growth inhibition in mut-p53 PDAC cell lines and xenografts 
respectively (Azmi et al. 2010a). Mechanistically using siRNA silencing it was proven that 
the p53 family member p73 (which is rarely mutated in PDAC and other cancers) was found 
to be responsible for the observed anticancer/anti-tumor effects. That the combination 
worked in a p53 null system (HCT116--) further reiterated that MI-319-cisplatin combination 
could effectively induce apoptosis through a p73 dependent mechanism. However, further 
in-depth mechanistic studies are warranted specifically in PDAC.   
The availability of potent and specific MDM2 inhibitors, such as Nutlin-3 and MI-219, has 
provided the opportunity to examine in detail the molecular mechanism of p53 activation. 
In competition with a p53-based peptide, Nutlin-3 and MI-219 bind with high affinity to 
MDM2 (Ki = 36 and 5 nmol/L, respectively). They block the intracellular MDM2-p53 
interaction and induce the accumulation of p53 and the activation of the p53 pathway in 
tumor and normal cells. Conventional genotoxic anticancer agents and radiation also induce 
the accumulation and activation of p53, but they do so by posttranslational modifications of 
p53, such as phosphorylation. In contrast, Nutlin-3 induces neither DNA damage nor p53 
phosphorylation in cells. Hence, small-molecule MDM2 inhibitors represent a new class of 
non-genotoxic agents that can reactivate the p53 function. Apart from regulating p53 recent 
studies have shown p53 independent functions of MDM2. In this regard Zhang and co-
workers have extensively reviewed a whole range on targets governed by MDM2 (Zhang 
and Zhang 2005). Targeting MDM2 by agents such as MI-219 or Nutlin may affect a myriad 
of other key cellular molecules that play significant role in cell growth and apoptosis. In-
depth mechanistic studies on the mode of action of inhibitors on MDM2 and the consequent 
p53 reactivation are lacking and it was of interest to us to explore the roles of crucial 
proteins that are involved in the regulation of p53. Activated p53 is known to be influenced 
by multiple post-translational control processes such as phosphorylation and acetylation 
that positively regulate p53 function (Stommel and Wahl 2005). Acetylation is an important 
epigenetic phenomenon in the biology of p53 (Gu et al. 2004; Ito et al. 2002). Upon stress, 
p53 is acetylated at Lys382 which enhances its DNA binding activity (Hasegawa and 
Yoshikawa 2008). Moreover, deacetylation of p53 by SIRT1 has been shown to repress p53 
mediated cell cycle regulation and apoptosis. SIRT1 is also known to deacetylate another 
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protein Ku70 which, in turn, interacts with Bax and is responsible for blocking Bax entry 
into mitochondria. Therefore, we sought to determine whether acetylation of p53 could be 
influenced by our inhibitors in PDAC cells. Indeed our results showed that MI-219 
treatment suppresses SIRT1 protein and simultaneously enhances acetylation of p53. Using 
state of the art Surface plasmon resonance techniques we studied the binding between MI-
319 or Nutlin-3 and Ku70 and our results confirm high affinity association between the two. 
Interestingly MI-219 treatment resulted in the suppression of Ku70 expression along with 
disruption of Ku70-Bax interaction. This observation is of great importance because it 
proves that MDM2 inhibitor not only blocks MDM2 which is its primary target but also 
suppresses two secondary targets the negative regulator ‘SIRT1’, which is a molecule that 
regulates p53 function and Ku70. Although it is too preliminary to confirm the true 
binding/interaction site of Ku70 or SIRT1 to MI-319, yet is can be speculated that MI-319 or 
Nutlin-3 may interact with peptide sequence (LSQETFSDLWKLL) similar to p53 
transactivation domain towards which both Nutlin-3 or MI series of inhibitors were built.  
As MI-219 does not alter MDM2 expression yet Ku70 and SIRT1 are suppressed suggesting 
that these drugs may have a MDM2 independent role in the biology of cells. However, 
compelling evidence in literature supports to a MDM2 dependent mechanism of action of 
these drugs on Ku70 and SIRT1. Our cell free FRET based SIRT1 activity assay showed 
inhibition of SIRT1 activity by MDM2 inhibitors. Yet in a cellular system the dynamics of 
SIRT1 is complex. Studies so far suggest that only wt-p53 can inhibit SIRT1 while cells that 
have lost or have mutations in p53 have over expressed SIRT1 and cannot repress it. This 
certainly points out that the suppression of SIRT1 in our system is p53 dependent however 
elucidation of the exact mechanism of action requires further work. As far as Ku70 is 
concerned, very recently Nutlin, a drug with similar mode of action as MI-219 was shown to 
disrupt MDM2-Ku70 interaction. Based on our results and those of others we propose 
multiple mode of action MI-219 on SIRT1 and Ku70. MDM2 inhibitors down regulate SIRT1 
that in principle may prevent Ku70 and p53 deacetylation. Surface plasmon resonance and 
Co-IP results confirm that MI drugs directly bind to Ku70 as well as disrupt Ku70-Bax 
interaction. Although yet to be proved, it is suggested that such a direct binding may induce 
conformational changes in Ku70 rendering it ineffective in binding to Bax and therefore 
allowing the latter to induce apoptosis. MI drugs also directly suppress Ku70 mRNA and 
protein expression which in turn allows p53 induced free Bax to mediate apoptotic events.  
Additionally, we have utilized a systems biology and network modeling approach to 
investigate in mechanistic detail the mechanism of action of MDM2 inhibitor and its 
oxaliplatin combination in PDAC (Azmi et al. 2010d; Azmi et al. 2011). Microarray profiling 
of a wt-p53–containing PDAC cell line (Capan-2) treated with either MI-219, oxaliplatin, or 
their combination, revealed some very interesting results that may have clinical 
implications. Global analysis of genes showed that MI-219 treatment resulted in the 
alteration of only 48 genes, which highlights the targeted nature of MDM2 inhibitor MI-219. 
On the other hand, oxaliplatin is a cytotoxic agent and caused alteration of 761 genes. The 
combination of MI-219 with oxaliplatin resulted in 767 genes being altered. The most 
important aspect of this finding is the emergence of 286 synergy-specific unique genes that 
were not found in the MI-219 alone or in the oxaliplatin-treated group. This finding 
confirms that the synergy between MI-219 and oxaliplatin is at the gene level. Principle 
component analysis showed that the global gene signatures between single treatments 
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versus combination treatments were non-overlapping and could be differentiated at 
different time points. Molecular network modeling of a total of 767 gene-associated 
pathways revealed a total of 22 statistically enriched functional groups that were linked to 
biologically distinct functional pathways. Interestingly, network modeling of the 286 
synergy-unique genes showed statistical enrichment of 14 disease (cancer) relevant 
pathways. This finding suggests that these pathways are relevant to cancer, further 
indicating that the combination synergy between MI-219 and oxaliplatin is at the gene level, 
comprising distinct biologically meaningful processes. Further analysis of the combination 
treatment network revealed the presence of several local networks, or hubs, rather than a 
single hub of activity interconnecting MDM2-p53. Central players such as the CREB binding 
protein (CREBBP; i.e., ubiquitously expressed gene) that is involved in the transcriptional 
coactivation of many different transcription factors, including p53, collaborates/cooperates 
with ARF (CARF) that is responsible for p53 stability, and NF-κB and early growth response 
protein (EGR1) tumor suppressor module, all of which are known to positively affect p53 
reactivation, which in principle would drive cells toward increased apoptosis. Most 
importantly, these observed gene changes could also be validated at the mRNA and  
protein level.  
Other investigators have also performed expression signature analysis of Nutlin-3. For 
example gene expression profiling of Nutlin-3 has been done by Zauli and group in B-cell 
lymphocytic leukemia (B-CLL) (Zauli et al. 2009). In their study B-CLL patient samples were 
exposed to Nultin-3 and cDNA expression profiling was performed. With the exception of a 
few cases, the authors noted induction of a characteristic gene expression profile (GEP) 
signature that was similar in the majority of B-CLL patient samples. Most significantly, lack 
of characteristic signatures correlated with poor response to Nutlin-3. However, partial lack 
of response in these wt-p53 B-CLL samples was not due to defects in the ability of Nutlin-3 
to promote p53 induction, but suggested the involvement of secondary masking 
mechanisms. Nutlin-3 gene signatures were all related to the p53 network and included 
downstream affector genes such as Fas and Bax and activation of auto-regulatory MDM2. 
Such type of biological analysis, if coupled with network modeling may provide further 
information on the entire set of genes modulated by Nutlin-3 in B-CLL patients. Results of 
these studies will significantly aid in the design of clinically successful drug combinations 
for other malignancies, which will ultimately benefit the overall survival of patients 
irrespective of the mutational and functional status of p53. In another study, a large-scale 
RNA interference–based short hairpin RNA (shRNA) barcode screen was applied to gain 
insight in the mechanism of action of Nutlin-3 (Brummelkamp et al. 2006). In this study it 
was shown that aside from p53, 53BP1 was critical mediator of Nutlin-3–induced 
cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is 
frequently activated in cancer but not in healthy tissues (DiTullio, Jr. et al. 2002). These 
results suggest that tumor specificity of Nutlin-3 may result from its ability to turn a cancer 
cell–specific property (activated DNA damage signaling) into a weakness that can be 
exploited therapeutically.  
5. Current status of MDM2 Inhibitors in the clinic 
Although proven to be successful in the laboratory in multiple cancer models, MDM2 
inhibitors or approaches that utilize reactivation of p53 have a long way to go before they 
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are acceptable in the clinic for PDAC. Currently some SMIs that reactivate the mut-p53 
through protein conformational changes are currently in Phase I clinical trials (Brown et al. 
2009). In addition to the potential clinical applications, discovery of the first MDM2 
antagonist, Nutlin-3a provided the initial proof of concept that inhibition of protein-protein 
interactions was a feasible approach to pharmaceutical design. Since that time, a deluge of 
patents and reports have disclosed a high number of diverse molecules showing potency 
and selectivity toward MDM2 at the same time lacking in solubility. Careful attention to 
medical chemistry was employed to improve bioavailability of these scaffolds leading to 
compounds with optimized PK properties. The intense labor of research has finally begun to 
bear fruit as demonstrated by the advancement of JNJ-26854165 and RG7112, into early 
phase clinical trials. Preliminary data from trials of both compounds suggest potential for 
advancement to Phase II trials and beyond. A few examples are PRIMA (Phase I APR-246), 
CP-31398 (Phase I) and PhiKan-08 (Phase I). SMIs that activate p53 through disruption of 
MDM2-p53 binding such as MI-219, Nutlin-3 are in phase I. RITA a p53 binding targeted 
agent, tenovin (SIRT1 inhibitor are still in a pre-clinical testing phase. Leptomycin B (a 
CRM1 (Exportin 1) binding agent that mediates p53 reactivation) is in Phase I while 
Actinomycin D (an RPL11 and RPL5 (Ribosomal protein L) releasing agent) has been 
approved for Phase I (Choong et al. 2009). Certain combinations such as nutlin with mitotic 
inhibitors for example BI-2536 (PLK1 (Polo-Like Kinase) inhibitor) or with VX680 (Aurora 
kinase inhibitor) are also in Phase I.  
6. Conclusion  
In PDAC, multiple de-regulated signaling especially the MDM2 over-expression and hyper 
activated K-ras driven pathways hone in on p53 and suppress its proper function in 
controlling various cellular processes. Studies indicate that these suppressive mechanisms 
render p53 re-activating genotoxic therapies ineffective. The well-studied role of p53 in 
coordinating cellular response to stress, aberrant growth signals and genomic instability has 
established a solid rationale for the targeting of MDM2 and K-ras driven snail to restore 
therapeutic response to treatment of PDAC. The entry of orally-administered MDM2 
antagonists into clinical trials represents a significant advancement for the field of small 
molecule drug discovery in PDAC.   
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